Physician assistants broke into the rank of the 10 most sought-after providers for the first time in 2013, according to Medicus Firm, a physician placement company. Medicus bases its findings on hiring activities in more than 200 hospitals and group practices nationwide. The demand for nonphysician providers will increase as the strains on primary care continue, Medicus says.

In addition to physician assistants, gastroenterologists made the top 10. OB/gyns and pediatricians dropped off the list.

Most sought-after providers
2012 2013
  1. Family practitioner
  2. Hospitalist
  3. Internist
  4. Pediatrician
  5. Neurologist
  6. General surgeon
  7. OB/gyn
  8. Orthopedic surgeon
  9. Emergency medicine doc
  10. Psychiatrist
  1. Family practitioner
  2. Hospitalist
  3. Internist
  4. General surgeon
  5. Orthopedic surgeon
  6. Physician assistant
  7. Neurologist
  8. Gastroenterologist
  9. Psychiatrist
  10. Emergency medicine doc
States most seeking physicians
2012 2013
Ohio
Pennsylvania
Mississippi
Texas
California
Massachusetts
Florida
Georgia
Tennessee
Kansas
Texas
Ohio
Georgia
Louisiana
Missouri
Arkansas
California
North Carolina
Massachusetts
Pennsylvania

The number of employers offering signing bonuses to potential physician employees declined a bit in 2013, something that surprised Medicus. “However, this could be simply a post-surge dip because of the volume and amounts of bonuses offered the previous year,” says Steve Marsh, a managing partner. “This statistic typically fluctuates and will most likely increase again as recruitment remains competitive for physicians, especially primary care.”

Percent of new providers offered signing bonus

Average amount of signing bonus

Source: “2013 Physician Placement Summary,” Medicus Firm, March 2014

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.